MedPath

First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO Guidelines

Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Valneva's Ixchiq: First Chikungunya Vaccine

The FDA has granted approval to Valneva's Ixchiq vaccine, making it the first-ever vaccine for the chikungunya virus, a mosquito-borne disease causing severe joint pain.
Ixchiq is approved for adults 18 and over at increased risk of chikungunya exposure, demonstrating a 98.9% antibody response rate in clinical trials 28 days post-vaccination.

Traws Pharma's Tivoxavir Marboxil Shows Promise as Single-Dose H5N1 Bird Flu Treatment

Traws Pharma's Tivoxavir Marboxil demonstrates encouraging results as a single-dose treatment for H5N1 avian influenza, marking a potential breakthrough.
Phase 1 trial data reveals that a single dose of Tivoxavir Marboxil maintains plasma drug levels above the effective concentration for over 23 days.

WHO Approves First Mpox Vaccine for Children Amid Outbreak Surge

The World Health Organization (WHO) has granted emergency use listing for the Lc16m8 mpox vaccine, the first approved for children aged one year and older.
This decision aims to increase access to vaccines in communities experiencing mpox outbreaks, particularly in regions like the Democratic Republic of Congo.

Chloroquine-Primaquine Efficacy Assessed for Vivax Malaria in the Colombian Amazon

A recent study in the Colombian Amazon evaluated the efficacy of chloroquine combined with primaquine for treating uncomplicated _Plasmodium vivax_ malaria.
Supervised treatment with chloroquine and primaquine over 7 or 14 days showed a 100% adequate response, highlighting the importance of treatment adherence.

Phase 1 Trial Launched for Long-Acting Injectable Malaria Preventive MMV371

Medicines for Malaria Venture (MMV) and Quotient Sciences have initiated a Phase 1 clinical trial for MMV371, a long-acting injectable malaria preventive.
The trial, conducted in healthy volunteers in the UK, will assess the safety, tolerability, and pharmacokinetics of the single-dose intramuscular injection.

WHO Approves Single-Dose Cecolin HPV Vaccine Following Landmark Trial

The WHO has approved Cecolin, a bivalent HPV vaccine, for single-dose use, potentially revolutionizing cervical cancer prevention efforts globally.
A clinical trial (CVIA 087) conducted by icddr,b and partners demonstrated the safety and efficacy of single-dose Cecolin vaccination.

WHO Prequalifies MVA-BN Mpox Vaccine, Boosting Global Access

The World Health Organization (WHO) has prequalified the MVA-BN vaccine, marking it as the first mpox vaccine to receive this designation, ensuring faster access.
This prequalification is based on data from Bavarian Nordic and a review by the European Medicines Agency, the regulatory agency of record for the vaccine.

WHO Prequalifies First Mpox Vaccine to Combat Outbreak in Africa

The World Health Organization (WHO) has prequalified the MVA-BN vaccine, manufactured by Bavarian Nordic, as the first vaccine against mpox.
This prequalification is expected to facilitate increased access to the vaccine in communities with urgent needs, particularly in Africa, to reduce transmission.

Novel Antibody-like Molecule Shows Promise for Broad-Spectrum Malaria Therapy

Researchers have discovered WD34, a novel antibody-like molecule, that inhibits malaria parasite infection at various disease stages.
WD34 binds to the AMA1 protein, common across malaria species, blocking the mechanism parasites use to enter liver and red blood cells.

Blood-stage Malaria Vaccine Candidate RH5.1/Matrix-M Trial in Tanzania

A phase 1b trial of the blood-stage malaria vaccine candidate RH5.1/Matrix-M has been conducted in healthy Tanzanian adults and children, marking a significant step in malaria vaccine development.

Reference News

[1]
First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO Guidelines
mmv.org · Dec 4, 2024

WHO prequalifies tafenoquine, the first single-dose treatment for preventing relapse of P. vivax malaria, co-administere...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy